JPS61227759A - Health-orienting food - Google Patents

Abstract

PURPOSE:The title food that contains an edible substance containing edible fibers soluble in water and viscous and a dry powder of SHIITAKE mushroom at a specific ratio, thus being capable of inhibiting overweight of body by abnormal accumulation of fat and increase in serum cholesterol accompanied therewith. CONSTITUTION:The objective health food contains (A) more than 5wt% of an edible substance containing edible fibers which are soluble in water and viscous, preferably glucomannan and (B) more than 5wt% of a dry powder of SHIITAKE mushroom, totaling over 10wt% in the food.

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention mainly relates to a health-oriented food that can suppress obesity caused by abnormal accumulation of fat in the human body and suppress an increase in blood cholesterol accompanying obesity.

[Conventional technology]

In an era of food sufficiency, overnutrition and unbalanced eating have led to a tendency toward obesity, and diseases such as diabetes and high blood pressure caused by obesity are on the rise.

In order to correct this tendency, in recent years, foods that are low in sweetness, low in salt, and low in fat have attracted attention in order to prevent excessive intake of nutrients, and glucomannan can be mentioned as one of them.

Glucomannan is dietary fiber/diet
It is a low-calorie food containing a large amount of mucilage as dietary fiber, which is typified by konnyaku, and is also collected from yuri machines.

Glucomannan is said to be deeply involved in the metabolism and excretion of lipids in the body, and is also said to be effective in suppressing the rise in blood cholesterol.

On the other hand, shiitake mushrooms also have the effect of lowering blood cholesterol, and dried shiitake mushrooms are said to contain about 40% dietary fiber.

[Problem that the invention seeks to solve]

Although glucomannan and shiitake mushrooms are considered to be effective as foods for preventing obesity in the human body and suppressing the rise in blood cholesterol associated with obesity, the amount of glucomannan and shiitake mushrooms that can be taken alone as food is far below the level that can be reasonably consumed as food. It cannot be said that effectiveness is necessarily satisfied.

For example, health-conscious foods and beauty foods made with glucomannan, which is known as a food whose main ingredient is glucomannan, keep you feeling full for a long time, leading to a loss of appetite. Such problems may occur.

[Means for solving problems]

In view of the above-mentioned problems with conventional health-oriented foods that suppress obesity and the rise in blood cholesterol caused by obesity, the inventors of the present invention have particularly focused on glucomannan, which suppresses the rise in blood cholesterol caused by obesity.
After repeated animal experiments on shiitake mushrooms, they discovered that a combination of these two foods can prevent obesity and lower blood cholesterol more efficiently than using either alone, leading to the completion of this invention. Ta.

In other words, the health-oriented food of the present invention contains edible water-soluble and viscous dietary fiber and dried shiitake mushroom powder each in an amount of 5% or more (wt%: the same applies hereinafter) in the total weight. It is characterized by the presence of

Examples of the water-soluble and viscous edible fiber containing dietary fiber used in the present invention include glucomannan and galactomannan.

Glucomannan exists alone or together with starch as a storage polysaccharide in the rhizomes of plants such as the above-mentioned konnyaku, orchidaceae, iris family, and lily family.

A typical example is konnyaku, which is a low-calorie food containing approximately 90% dietary fiber.

Further, galactomannan can be obtained from the seeds of the Goupoogam Sesameaceae family. ) can be mentioned.

On the other hand, eritadenine in shiitake mushrooms is said to have the effect of lowering blood cholesterol, and as mentioned above, shiitake mushrooms contain about 40% dietary fiber.

These edible water-soluble and viscous dietary fibers and dried shiitake mushroom powder each account for 5% or more in the total amount of the food, that is, the total amount of both components is at least 1%.
The content is no less than 0%.

If both of these are less than 5%, the absolute amount of components necessary for suppressing obesity and suppressing rise in blood cholesterol, such as dietary fiber in the food, is actually insufficient, and the intended purpose cannot be achieved.

Also, if either of these two is less than 5%,
Due to the unbalance in the amounts of both in the food, the desired purpose cannot be met.

As mentioned above, the amount of edible water-soluble and viscous dietary fiber and dried shiitake mushroom powder in the total amount of health-conscious food should be 5% or more, and the higher the percentage, the better the prevention and obesity. It is effective in suppressing the rise in blood cholesterol caused by.

However, considering the taste as a health food and the ease of ingestion, it is desirable to mix it with other compounds.

There are no special restrictions on the compound and its compound composition, but casein, cellulose, and minerals may be included.

Vitamins, high quality fatty acids such as cornstarch and cottonseed oil, sugar, etc. can be added as appropriate.

Products containing such ingredients may be prepared as is, or they may be kneaded and hardened to form a sheep-like solid food, or the kneaded and hardened product may be rolled out into a thin layer and dried to form a rice cracker-like dry solid food. This makes it possible to create an easily edible health food.

[For production]

In this invention, the health-oriented food obtained by combining the above-mentioned dietary fiber-containing edible and dried shiitake mushroom powder has the following effects:
As is clear from the experimental examples described later, the effect of suppressing obesity and increasing blood cholesterol is superior to that obtained by combining these alone, and it is clear that a synergistic effect between the two is observed. be.

〔Example〕

The present invention will be described in more detail below with reference to experimental examples using mice in which the health-oriented food of the present invention containing glucomannan and dried shiitake mushroom powder was used as feed.

When gold thioglucose (hereinafter referred to as rGTG) is administered to scissor-superior mice, the ventromedial hypothalamus (feeding center) is destroyed and obesity is established.

That is, abnormal accumulation of fat occurs in the body. in this case,
Hyperinsulinemia is considered to be the primary factor.

The inventor used this GTG-administered mouse as a model to ingest feed containing glucomanan according to the present invention and dried shiitake mushroom powder, and examined the state of obesity and lipid metabolism.

In this case, one group of mice made obese by administration of GTG was fed a feed containing the glucomanan and dried shiitake mushroom powder (this is referred to as obese group (1)).
, the other group is fed with feed that does not contain GTG and is referred to as the obese group (2)), and another group is prepared in which GTG is not separately administered (this is referred to as the normal group).
The same diet as in 2) was given, and the obese group (2) and normal group were compared with the obese group (1).

That is, medium-sized ICR female mice weighing 22 to 26 g were preliminarily fed with solid feed for one week, and only mice with no growth abnormalities were selected and used for the experiment.

During this pre-breeding and experimental period, the animals were given free access to feed and water, and the temperature of the breeding room was 22-26°C, and the humidity was 50-50°C.
70% and a 12 hour light/dark cycle.

In this experiment, the mice were divided into 3 groups as described above, each group having 15 mice, and 5 mice each were housed in breeding cages.

Two groups of mice in each of these groups were preliminarily administered an aqueous solution of GTG intraperitoneally at a dose of 0.7 g/kg of mouse body weight, and preliminarily housed for 4 days through the administration port. Obese groups (1), (2) composed of obese mice
The other group was a normal group consisting of normal mice to which GTG was not administered.

The two groups of obese mice treated with GTG and the group of normal mice were fed feeds with the composition shown in Table 1 and kept for 8 weeks.

During this feed administration period, feed was given in the morning every day, and body weights were measured once a week.

[Margin below]

Table 1: The weight of each group of mice was measured on the last day of each week of the experimental period, and the results shown in Table 2 were obtained.

[Margin below]

Table 2 (same for the following tables) Note: The letters on the shoulders of the snow values indicate the obese group (2
) is added to indicate the value of significant difference.
These significant differences are as follows. (The same applies to the table below)a
p<0.01b;p<0.025
cip < 0.05 dip < 0.1 The mice of each group reared in this way were taken out of the breeding cage on the last day of the 8-week experimental period, and after being allowed to sit for 16 hours, their weight was measured, and they were placed under ether anesthesia. Animals were sacrificed by bleeding from the heart.

Thereafter, 0.9% physiological saline was refluxed to thoroughly remove blood from the liver, and the liver and parauterine adipose tissue were collected, and their weights were immediately measured.

The results are shown in Table 3 along with the amount of weight gain.

[Margin below]

The blood was then left in ice water for about 1 hour, and then 3000
Plasma was separated by centrifugation at rpm for 15 minutes.

Regarding this plasma, total cholesterol (hereinafter referred to as T-cho)
(abbreviated as 1), triglyceride (hereinafter referred to as T, G).

), lipid peroxide (hereinafter abbreviated as T, B, and A), and transaminases were measured.

The results are shown in Table 4.

[Margin below]

In addition, the measurement of T-chol is carried out using Cholesterol B-testwa: 2. -, T, and G measurements are triglyceride C-
■-Test Wako, transaminase is GPT-Uv
Test Wako and GOT-UV Test Wako devices (both manufactured by Wako Pure Chemical Industries, Ltd.) were used.

Next, T-chol for mouse liver.

Phospholipids (hereinafter abbreviated as P), T, B, A, and chemiluminescence were measured.

These are shown in Table 5.

In addition, these liver lipids were obtained by collecting approximately 0.8 g of liver and homosinating it in a mortar with anhydrous sodium sulfate.
QT-chol is extracted with chloroform-methanol (2:1) and used as an extract to measure each lipid.QT-chol is a cholesterol-B test Wako.

T and G were measured with Triglyceride Test Wako, P and L were measured with Phospholipid B-Test Wako (all manufactured by Wako Pure Chemical Industries, Ltd.), T, B and A were measured with the Uchiyama-Mihara method, and Chem. Luminescence is Cheseilu+wine
Measurement was performed at 37° C. using an open cell with science Analyzen 0x-7.

The significance of each experimental result was determined by t-test.

[Margin below]

Note in Table 5), there was a significant difference in the obese group from (2) a; p<0.005 b; p<0.0
5 [Margin below] In these Tables 2 to 5, the increase in body weight was significantly lower in the obese group (1) than in the obese group (2) throughout the 8 weeks of the experimental period (Table 2).

The amount of weight gain was similarly low, and when comparing the weight of parauterine adipose tissue, which is an indicator of obesity, and its ratio to body weight, significant differences were also found (Table 3).

From the above, it can be concluded that foods containing glucomannan and shiitake mushrooms have the effect of suppressing obesity in GTG-treated obese mice.

Next, regarding plasma lipids and transaminases, although triglyceride levels increased in the obese group (1),
Cholesterol levels were significantly reduced, indicating that the cholesterol-lowering effects of glucomannan and shiitake mushrooms were working to their full potential, suppressing the rise in cholesterol levels associated with obesity.

Transaminases, which are an indicator of whether liver function is working normally, were normal in all three groups (
Table 4).

There was no big difference in liver lipids between the groups, but both the triglyceride content and total lipid content were higher in the obese group (1) than in the obese group (2).
) (Table 5).

This indicates that fat accumulation is suppressed by glucomannan and shiitake mushrooms.

There were no major differences in lipid peroxide and chemiluminescence between the groups (Table 5), and it is thought that there was no effect on lipid peroxide in the blood and liver in this experiment.

To summarize the above, the food related to this invention containing 5% each of glucomannan and dried shiitake mushrooms suppresses abnormal accumulation of tissue fat and lowers blood cholesterol in obesity in mice with hypothalamic dysplasia caused by GTG. It is clear that it has a decreasing effect.

〔Effect of the invention〕

As is clear from the above experimental examples, the health-oriented food of the present invention, which essentially uses a specific amount of water-soluble and viscous dietary fiber, especially glucomannan and dried shiitake mushroom powder, Due to both of these components, it exhibits a remarkable lipid metabolic function compared to a product that lacks these components either directly or in specific amounts, and greatly contributes to suppressing obesity and thereby suppressing the rise in blood cholesterol.

In addition, the health-oriented food of this invention uses glucomannan and shiitake mushrooms, which are known as inherently safe and harmless foods, so it is safe and has no adverse effects on the human body, and is ideal for health. As food, it should be evaluated as fat.

Furthermore, both of the above essential ingredients are inexpensive and have been commonly used for a long time.

Therefore, the health-oriented food obtained by this invention is also inexpensive, and in this respect, the invention is of great utility.

Patent Applicant Mori Sangyo Co., Ltd. Agent Patent Attorney Yuki 1) Written amendment to all Hong Kong procedures 1, Indication of the case 1985 Patent Application No. 070541 2, Name of the invention Health-oriented food 3, Person making the amendment Case and Relationship: Patent Applicant: 1-2-23 Nishikuta-cho, Kiryu-shi, Gunma Prefecture Mori Sangyo Co., Ltd. Representative: Kimio Mori 4, Agent 8105: 5-12-1 Shinbashi, Minato-ku, Tokyo Detailed description of the invention specified in Specification 4 Column ゎ6. In Table 1 on page 10 of the Specification of Contents of the Amendment, "casein" is corrected to "casein."

that's all

Claims (2)

[Claims] (1) A health-oriented food characterized by containing an edible water-soluble and viscous dietary fiber and dried shiitake mushroom powder in an amount of 5% by weight or more, respectively. (2) The health-oriented food according to claim 1, wherein the edible material is glucomannan.